A Systematic Prospective Comparison of Noninvasive Disease Activity Indices in Ulcerative Colitis

Clinical Gastroenterology and Hepatology

Volumn 7, Issue 10, 2009, Pages 1081-1088

  Turner, Dan ^a   Seow, Cynthia H ^b   Greenberg, Gordon R ^b   Griffiths, Anne M ^c   Silverberg, Mark S ^b   Steinhart, A Hillary ^b  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b MOUNT SINAI HOSPITAL   (Canada)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BLOOD EXAMINATION; CLINICAL PRACTICE; COLONOSCOPY; CONTROLLED STUDY; DISEASE ACTIVITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT ASSESSMENT; PHYSICIAN; PROSPECTIVE STUDY; TEST RETEST RELIABILITY; ULCERATIVE COLITIS;

ADOLESCENT; ADULT; ANIMALS; BIOLOGICAL MARKERS; COLITIS, ULCERATIVE; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 70349508834     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2009.06.024     Document Type: Article

References (53)

1. Beattie R.M., Nicholls S.W., Domizio P., et al. Endoscopic assessment of the colonic response to corticosteroids in children with ulcerative colitis. J Pediatr Gastroenterol Nutr 22 (1996) 373-379
2. Sands B.E. Biological therapies for ulcerative colitis. Acta Gastroenterol Belg 64 (2001) 205-209
3. D'Haens G., Sandborn W.J., Feagan B.G., et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 132 (2007) 763-786
4. Best W.R., Becktel J.M., Singleton J.W., et al. Development of a Crohn's disease activity index: National Cooperative Crohn's Disease Study. Gastroenterology 70 (1976) 439-444
5. Kirshner B., and Guyatt G. A methodological framework for assessing health indices. J Chronic Dis 38 (1985) 27-36
6. Wright J.G., and Feinstein A.R. A comparative contrast of clinimetric and psychometric methods for constructing indexes and rating scales. J Clin Epidemiol 45 (1992) 1201-1218
7. Marx R.G., Bombardier C., Hogg-Johnson S., et al. Clinimetric and psychometric strategies for development of a health measurement scale. J Clin Epidemiol 52 (1999) 105-111
8. Noble A., and Turner D. Clinical outcomes in pediatric inflammatory bowel disease. In: Mamula P., Markowitz J., and Baldassano R. (Eds). Pediatric inflammatory bowel disease. 1st ed. (2008), Springer, New York, NY 744
9. Assessing health status and quality-of-life instruments: attributes and review criteria. Qual Life Res 11 (2002) 193-205
10. Irvine E.J., Feagan B., Rochon J., et al. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease: Canadian Crohn's Relapse Prevention Trial Study Group. Gastroenterology 106 (1994) 287-296
11. Yoshida E.M. The Crohn's Disease Activity Index, its derivatives and the Inflammatory Bowel Disease Questionnaire: a review of instruments to assess Crohn's disease. Can J Gastroenterol 13 (1999) 65-73
12. Seo M., Okada M., Yao T., et al. An index of disease activity in patients with ulcerative colitis. Am J Gastroenterol 87 (1992) 971-976
13. Walmsley R.S., Ayres R.C., Pounder R.E., et al. A simple clinical colitis activity index. Gut 43 (1998) 29-32
14. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ 298 (1989) 82-86
15. Azzolini F., Pagnini C., Camellini L., et al. Proposal of a new clinical index predictive of endoscopic severity in ulcerative colitis. Dig Dis Sci 50 (2005) 246-251
16. Turner D., Otley A.R., Mack D., et al. Development and evaluation of a Pediatric Ulcerative Colitis Activity Index (PUCAI): a prospective multicenter study. Gastroenterology 133 (2007) 423-432
17. Lichtiger S., and Present D.H. Preliminary report: cyclosporin in treatment of severe active ulcerative colitis. Lancet 336 (1990) 16-19
18. Truelove S.C., and Witts L.J. Cortisone in ulcerative colitis: final report on a therapeutic trial. Br Med J (1955) 1041-1048
19. Maunder R.G., and Greenberg G.R. Comparison of a disease activity index and patients' self-reported symptom severity in ulcerative colitis. Inflamm Bowel Dis 10 (2004) 632-636
20. Walsh A.J., Brain A.O.S., Keshav S., et al. Which activity index for ulcerative colitis (UC)?. Evaluation of inter-observer variation in clinical, endoscopic and composite indices. J Crohn Colitis 3 (2009) S45 (P086)
21. Higgins P.D., Leung J., Schwartz M., et al. The quantitative validation of non-endoscopic disease activity indices in ulcerative colitis. Aliment Pharmacol Ther 25 (2007) 333-342
22. Winther K.V., Fogh P., Thomsen O.O., et al. Inflammatory bowel disease (ulcerative colitis and Crohn's disease): diagnostic criteria and differential diagnosis. Drugs Today (Barc) 34 (1998) 935-942
23. Mary J.Y., and Modigliani R. Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study: Groupe d'Etudes Therapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut 30 (1989) 983-989
24. Gomes P., du Boulay C., Smith C.L., et al. Relationship between disease activity indices and colonoscopic findings in patients with colonic inflammatory bowel disease. Gut 27 (1986) 92-95
25. Kundhal P.S., Critch J.N., Zachos M., et al. Pediatric Crohn Disease Activity Index: responsive to short-term change. J Pediatr Gastroenterol Nutr 36 (2003) 83-89
26. Beurskens A.J., de Vet H.C., and Koke A.J. Responsiveness of functional status in low back pain: a comparison of different instruments. Pain 65 (1996) 71-76
27. de Vet H.C., Ostelo R.W., Terwee C.B., et al. Minimally important change determined by a visual method integrating an anchor-based and a distribution-based approach. Qual Life Res 16 (2007) 131-142
28. Guyatt G., Walter S., and Norman G. Measuring change over time: assessing the usefulness of evaluative instruments. J Chronic Dis 40 (1987) 171-178
29. Higgins P.D., Schwartz M., Mapili J., et al. Patient defined dichotomous end points for remission and clinical improvement in ulcerative colitis. Gut 54 (2005) 782-788
30. Shrout P., and Fleiss J. Intraclass correlations: uses in assessing rater reliability. Psychol Bull 86 (1979) 420-428
31. Schunemann H.J., Puhan M., Goldstein R., et al. Measurement properties and interpretability of the chronic respiratory disease questionnaire (CRQ). Copd 2 (2005) 81-89
32. Schroeder K.W., Tremaine W.J., and Ilstrup D.M. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis: a randomized study. N Engl J Med 317 (1987) 1625-1629
33. Sutherland L.R., Martin F., Greer S., et al. 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology 92 (1987) 1894-1898
34. Powell-Tuck J., Bown R.L., and Lennard-Jones J.E. A comparison of oral prednisolone given as single or multiple daily doses for active proctocolitis. Scand J Gastroenterol 13 (1978) 833-837
35. Turner D., Hyams J., Markowitz J., et al. Appraisal of the pediatric ulcerative colitis activity index (PUCAI). Inflamm Bowel Dis 15 (2009) 1218-1223
36. Turner D., Walsh C.M., Benchimol E.I., et al. Severe paediatric ulcerative colitis: incidence, outcomes and optimal timing for second-line therapy. Gut 57 (2008) 331-338
37. Seo M., Okada M., Maeda K., et al. Correlation between endoscopic severity and the clinical activity index in ulcerative colitis. Am J Gastroenterol 93 (1998) 2124-2129
38. Seo M., Okada M., Yao T., et al. Evaluation of disease activity in patients with moderately active ulcerative colitis: comparisons between a new activity index and Truelove and Witts' classification. Am J Gastroenterol 90 (1995) 1759-1763
39. Turner D., Schünemann H.J., Griffith L.E., et al. The minimal detectable change cannot reliably replace the minimal important difference. J Clin Epidemiol (2009) [Epub ahead of print]
40. Turner D., Griffiths A.M., Steinhart A.H., et al. Mathematical weighting of a clinimetric index (Pediatric Ulcerative Colitis Activity Index) was superior to the judgmental approach. J Clin Epidemiol 62 (2009) 738-744
41. Xiang J.Y., Ouyang Q., Li G.D., et al. Clinical value of fecal calprotectin in determining disease activity of ulcerative colitis. World J Gastroenterol 14 (2008) 53-57
42. Beattie R.M., Walker-Smith J.A., and Murch S.H. Indications for investigation of chronic gastrointestinal symptoms. Arch Dis Child 73 (1995) 354-355
43. Jarnerot G., Hertervig E., Friis-Liby I., et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 128 (2005) 1805-1811
44. Walsh A.J., Brain A.O.S., Keshav S., et al. How variable is the Mayo score between observers and might this affect trial recruitment or outcome?. J Crohn Colitis 3 (2009) S71 (P151)
45. Sinha A., Nightingale J., West K.P., et al. Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis. N Engl J Med 349 (2003) 350-357
46. Marteau P., Probert C.S., Lindgren S., et al. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study. Gut 54 (2005) 960-965
47. Sandborn W.J., Tremaine W.J., Schroeder K.W., et al. A placebo-controlled trial of cyclosporine enemas for mildly to moderately active left-sided ulcerative colitis. Gastroenterology 106 (1994) 1429-1435
48. Sandborn W.J., Tremaine W.J., Offord K.P., et al. Transdermal nicotine for mildly to moderately active ulcerative colitis: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 126 (1997) 364-371
49. Rutgeerts P., Sandborn W.J., Feagan B.G., et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 353 (2005) 2462-2476
50. Sandborn W.J., Sands B.E., Wolf D.C., et al. Repifermin (keratinocyte growth factor-2) for the treatment of active ulcerative colitis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Aliment Pharmacol Ther 17 (2003) 1355-1364
51. Rutgeerts P. Comparative efficacy of coated, oral 5-aminosalicylic acid (Claversal) and sulphasalazine for maintaining remission of ulcerative colitis: International Study Group. Aliment Pharmacol Ther 3 (1989) 183-191
52. Targan S.R., Salzberg B.A., Mayer L., et al. A phase I-II study: multiple dose levels of visilizumab are well tolerated and produce rapid and sustained improvement in ulcerative colitis patients refractory to treatment with IV steroids (IVSR-UC). Gastroenterology 128 Suppl 2 (2005) A75
53. Silverberg M.S., Satsangi J., Ahmad T., et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 19 Suppl A (2005) 5-36